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A reverse genetics approach was utilized to discover new pro-
teins that interactwith themitochondrial fusionmediatormito-
fusin 2 (Mfn2) and thatmay participate inmitochondrial fusion.
In particular, in vivo formaldehyde cross-linking of whole HeLa
cells and immunoprecipitationwith purifiedMfn2 antibodies of
SDS cell lysates were used to detect an 42-kDa protein. This
protein was identified by liquid chromatography and tandem
mass spectrometry as stomatin-like protein 2 (Stoml2), previ-
ously described as a peripheral plasma membrane protein of
unknown function associated with the cytoskeleton of erythro-
cytes (Wang, Y., and Morrow, J. S. (2000) J. Biol. Chem. 275,
8062–8071). Immunoblot analysis with anti-Stoml2 antibodies
showed that Stoml2 could be immunoprecipitated specifically
withMfn2 antibody either from formaldehyde-cross-linked and
SDS-lysed cells or from cells lysed with digitonin. Subsequent
immunocytochemistry and cell fractionation experiments fully
supported the conclusion that Stoml2 is indeed amitochondrial
protein. Furthermore, demonstration of mitochondrial mem-
brane potential-dependent import of Stoml2 accompanied by
proteolytic processing, together with the results of sublocaliza-
tion experiments, suggested that Stoml2 is associated with the
inner mitochondrial membrane and faces the intermembrane
space. Notably, formaldehyde cross-linking revealed a “lad-
der” of high molecular weight protein species, indicating the
presence of high molecular weight Stoml2-Mfn2 hetero-oli-
gomers. Knockdown of Stoml2 by the short interfering RNA
approach showed a reduction of the mitochondrial mem-
brane potential, without, however, any obvious changes in
mitochondrial morphology.
MammalianmitofusinsMfn1 andMfn2 are largeGTPases of
the mitochondrial outer membrane that mediate mitochon-
drial fusion (1–3). They also contain two coiled-coil domains or
heptad repeats (HR1 and HR2)2 (3). The major portion of each
of the proteins, including the N terminus-proximal GTPase
domain andHR1 and the C terminus-proximal HR2, is exposed
to the cytosol (4). The attachment to the outer membrane is
mediated by two membrane-spanning segments that are sepa-
rated by a small intermembrane space loop and that are located
between theHR1 andHR2 repeats. HumanMfn1 andMfn2 are
highly homologous proteinswith 62% identity at the amino acid
levelwith both, however, being essential proteins. The homozy-
gous / Mfn1-null and / Mfn2-null mice die during
embryonic development (5). The mouse embryonic fibroblasts
(MEF), derived from the / Mfn1-null or / Mfn2-null
embryos, have distinct mitochondrial morphology defects, and
exhibit severe reduction in mitochondrial fusion activity (5).
Thus, Mfn1 and Mfn2 may have different functions in mito-
chondrial fusion. UnlikeMEF lackingMfn1 orMfn2,MEF lack-
ing both mitofusins completely lack mitochondrial fusion
capacity and show severe cellular dysfunction (6). Functions of
Mfn2 that are independent of its fusion activity, i.e. controlling
mitochondrial metabolism and repressing vascular smooth
muscle cell proliferation, have also been reported (7, 8).
Mfn2 andMfn1 have the capacity to formhomo- and hetero-
oligomers, as demonstrated by co-immunoprecipitation of
tagged proteins (5, 9). At least one of the mitofusins is required
on each of the adjacent mitochondria to promote mitochon-
drial fusion (10). The initial step of this process is characterized
by tethering of two adjacent mitochondria via assembly of a
mitofusin complex, which is mediated by HR2 forming a
dimeric, antiparallel coiled-coil (10). The subsequent steps of
mitochondrial fusion, including the exact function of the
GTPase domains, are less well understood. In yeast, an interac-
tion of the mitofusin homolog Fzo1, involving the GTPase
domain and the HR domains, is essential for fusion (11). In the
same organism,mitochondrial fusion has been reconstituted in
vitro. Mitochondrial fusion proceeds through discreet and
sequential mitochondrial outer and inner membrane fusion
events, with both steps requiring GTP hydrolysis (12). A third
GTPase, Opa1, appears also to be involved in the process of
mitochondrial fusion (13). This GTPase is synthesized as a pre-
cursor, which is processed by a matrix-processing peptidase to
a mature form, large Opa1 (l-Opa1). l-Opa1 is anchored to the
inner mitochondrial membrane and can undergo another pro-
teolytic processing, which cleaves off the transmembrane seg-
ment and forms the small form (s-Opa1) (14). In both yeast and
mammals, the mitochondrial morphology is regulated through
this proteolytic processing of Opa1 (Mgm1) in anATP ormito-
chondrial membrane potential-dependent manner (14–17).
Interestingly, Opa1-mediated fusion was reported to depend
onMfn1 but not onMfn2 (18). The detailed differences inMfn1
andMfn2 function are, however, unclear at present. In yeast, an
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additional protein, Ugo1, which participates in mitochondrial
fusion, has been identified (19, 20). This protein spans the outer
mitochondrial membrane and interacts, via its N terminus-
proximal cytosolic domain, with Fzo1 and, via its C terminus-
proximal intermembrane space domain, withMgm1, thus link-
ing the outer and the inner membrane fusion machinery.
However, neither an Ugo1 homolog nor additional proteins
that facilitate mitochondrial fusion have been identified in
mammals.
In this study, we have identified a novel complex containing
Mfn2 and Stoml2. Our results suggest that Stoml2 is a novel
mitochondrial intermembrane space/inner membrane-local-
ized protein that forms a large hetero-oligomeric complex with
Mfn2.
EXPERIMENTAL PROCEDURES
Plasmid Construction and in Vitro Transcription/
Translation—To construct a plasmid encoding a His-tagged
protein corresponding to amino acids 1–405 of Mfn2 (His-
Mfn2-(1–405)), a 1215-nucleotide-long fragment of an MFN2
cDNA was amplified by PCR from pBSKIAA0214, which car-
ries a human heart cDNA of MFN2 (21), and cloned into the
NdeI-BamHI sites of pET-15b. The resulting pET-15b/Mfn2-
(1–405) construct was verified by sequencing. To prepare an
Mfn2 mammalian expression plasmid, a 4550-nucleotide-
longHindIII-NotI fragment of pBSKIAA0214 (21), carrying the
entireMFN2 cDNA, was cloned into the HindIII and NotI sites
of pcDNA3 (Invitrogen).
To prepare a Stoml2 expression plasmid, poly(A) RNA iso-
lated from HeLa cells was reverse-transcribed and PCR-ampli-
fied using the Superscript One-Step reverse transcriptase-PCR
system (Invitrogen). The resulting 1107-nucleotide-long frag-
ment containing the entire open reading frame of STOML2was
subcloned into pGEM-Easy T (Promega) and verified by
sequencing. An EcoRI fragment containing the entire open
reading frame of STOML2 was further cloned into pcDNA3,
and a clone of pcDNA3/Stoml2 with the correct orientation
with respect to the cytomegalovirus promoter was selected.
Cell Lines, Transfection, and siRNA Treatment—The HeLa
human cell line (ATCCCCL-2) was grown in high glucose Dul-
becco’s modified Eagle’s medium (DMEM; containing 4.5 g/
liter glucose and 110 mg/liter sodium pyruvate, Invitrogen),
supplemented with 10% fetal bovine serum. HeLa S3 (ATCC
CCL-2.2), suspension-adapted HeLa cells, were grown as
described (22). For transient expression experiments, cells were
transfected with pcDNA3-derived plasmids using FuGENE 6
(Roche Applied Science) and incubated for 36 h to allow
transgene expression. For RNA interference-mediated knock-
down experiments, cells were transfected with 20 nM siRNA
directed against STOML2mRNA orMFN2mRNA (siGENOME
SMART pool, Dharmacon) using Dharmafect I (Dharmacon),
according the manufacturer’s protocol, and incubated for 4
days to reduce Stoml2 or Mfn2 protein levels. In some experi-
ments involving siRNASTOML2, cells were also transfected for a
second time, on the third day, and incubated for a total of 6
days.
Antibodies—His-Mfn2-(1–405) proteinwas expressed in the
Escherichia coli strain BL21(DE3), and the recombinant protein
was purified on nickel-nitrilotriacetic acid-agarose according
to the manufacturer’s protocol (Qiagen). The purified protein
was used to generate antibodies in rabbits (Covance). The anti-
Mfn2 antibodies were then blot-purified as described (23). The
preparation and purification of anti-Mfn1 antibodies has been
described (2). The following antibodies were also used: mouse
anti-Bcl-2 monoclonal antibodies (Santa Cruz Biotechnology),
goat anti-enolase polyclonal antibodies (Santa Cruz Biotech-
nology), rabbit anti-COXII serum (24), mouse anti-COXIV
monoclonal antibodies (Molecular Probes), mouse anti-F1-
ATPase -subunit monoclonal antibodies (Mitosciences),
mouse anti-porin monoclonal antibodies (Calbiochem), rab-
bit anti-prohibitin polyclonal antibodies (Lab Vision),
mouse anti-Opa1 monoclonal antibodies (BD Transduction
Laboratories), chicken anti-Stoml2 (N-180) polyclonal IgY
antibodies (Genway), chicken anti-Stoml2 (C-186) poly-
clonal IgY antibodies (Genway), mouse anti--tubulin
monoclonal antibodies (Oncogene), and rabbit anti-actin
polyclonal antibodies (Sigma).
Isolation and Purification of Mitochondria—Adherent cells
were harvested from 20 T-175 flasks by trypsinization, washed
once in PBS (140 mM NaCl, 3.8 mM NaH2PO4, 16.2 mM
Na2HPO4) containing 10% calf serum and twice in NKMbuffer
(0.13MNaCl, 5mMKCl, 7.5mMMgCl2, 10mMTris-HCl, pH7.4
(25 °C)). Cells in suspension culture, exponentially growing in a
3-liter volume, were harvested and washed twice in NKM
buffer. The washed cells were resuspended in six volumes (rel-
ative to the packed cells) of TKM buffer (10 mM Tris-HCl, pH
6.7 (25 °C), 10mMKCl, 0.15mMMgCl2) containing a Complete
Mini protease inhibitor mixture (Roche Applied Science) and,
after 2 min, were disrupted with a motor-driven Potter-Elve-
hjem glass-Teflon homogenizer until 60–75% of the nuclei
had been released (22). The remainder of the preparation of the
mitochondria-enriched fraction was as described (22). The
mitochondria were further purified by centrifugation through a
discontinuous Percoll/metrizamide gradient as described (25,
26) but using an SW41 rotor. The purified mitochondria were
washed and resuspended in STKM buffer (0.25 M sucrose in
TKM) and stored at80 °C.
Submitochondrial Localization and Import of Stoml2—For
membrane association studies, purified mitochondria (1
mg/ml) were incubated in a buffer (0.05 mM EDTA, Complete
Mini protease inhibitor mixture, EDTA-free (Roche Applied
Science), 20mMHEPES, pH 7.5 (25 °C)) for 15min on ice. Then
the same volume of distilledH2O, 3.0 MNaCl, 0.2 MNa2CO3, or
2% Triton X-100 was added, and incubation was continued for
30 min. Samples were centrifuged at 100,000 gav for 30 min,
and both pellet and supernatant fractions were analyzed by
Western blotting.
For protease sensitivity studies, import-competent mito-
chondria (2 mg/ml) were incubated with 0.5 mg/ml proteinase
K in a buffer (25 mM sucrose, 75 mM sorbitol, 100 mM KCl, 10
mM KH2PO4, 0.05 mM EDTA, 5 mM MgCl2, 10 mM Tris-HCl,
pH7.4 (25 °C)) in the presence of digitonin, as specified in Fig. 4,
for 30 min on ice. The reaction was stopped by the addition of
phenylmethylsulfonyl fluoride (5 mM final) and an equal vol-
ume of 2 Sample buffer (20% glycerol, 10% -mercaptoetha-
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nol, 4% SDS, 125 mM Tris-HCl, pH 6.8 (25 °C)). The samples
were boiled for 5 min and analyzed by Western blotting.
Preparation of import-competent mitochondria and import
of protein into isolated mitochondria were carried out as
described (27). The Stoml2was synthesized in the rabbit reticu-
locyte lysate-based TNT T7-coupled transcription/translation
system (Promega), in the presence of [35S]methionine (Amer-
sham Biosciences), according the manufacturer’s protocol.
[35S]Met Labeling, Formaldehyde (FA) Cross-linking, and
Immunoprecipitation—To label cells with [35S]methionine,
1.6 106 cells were grown in a 55-cm2 plate containing 4 ml of
low methionine (2  102 mM methionine)-DMEM supple-
mented with 10% dialyzed fetal bovine serum in the presence of
0.5 mCi Expre35S35S protein labeling mixture (1000 Ci/mmol)
for 16 h.After the labeling period, the cellswerewashed twice in
regular culture medium and processed for FA cross-linking.
35S-Labeled or unlabeled cells were scraped with a rubber
policeman and resuspended in culture medium (2  106/10
ml). The cell suspension was mixed with a one-tenth volume of
11% FA (Polysciences) in PBS and incubated under mixing for
1–15 min at room temperature. Then, an equal volume of 250
mMglycine in PBSwas added, and incubationwas continued for
15 min to quench the unreacted FA. The cells were recovered
by centrifugation and washed sequentially in PBS containing
1% bovine serum albumin and PBS.
For denaturing immunoprecipitation, 1  106 cells were
lysed in 0.05 ml of buffer A (1% SDS, 1 mM EDTA, 50 mM
Tris-HCl, pH 7.5 (25 °C)) with vortexing in the presence of
acid-washed glass beads. Then 0.85 ml of Tween-IP buffer
(0.5%Tween 20, 150mMNaCl, 0.1mMEDTA, 50mMTris-HCl,
pH 7.5 (25 °C)) containing the Complete Mini protease inhibi-
tor mixture was added, and insoluble debris were removed by
centrifugation at 16,000  gav for 10 min. The supernatants
(same amounts of total proteins) were incubated with the
appropriate purified rabbit antibodies for 3 h at 4 °C. Then, 0.05
ml of the protein A-Sepharose suspension (100 mg of protein
A-Sepharose (Sigma)/2.8 ml of a buffer (1 mg/ml bovine serum
albumin, 1mMNaN3, 10mMTris-HCl, pH 7.5)) was added, and
the incubation was continued for 30 min. The immune com-
plexes captured on Sepharose beadswere centrifuged through a
sucrose cushion (3.42 g of sucrose/10 ml of Tween-IP buffer),
washed twice with Tween-IP buffer and once with 1% 2-mer-
captoethanol, and solubilized in Sample buffer (10% glycerol,
5% -mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.8
(25 °C)). To reverse the cross-linking, the resulting samples
were heated to 95 °C for 25min. The proteinswere separated by
SDS-PAGEanddetected by autoradiography or, after the trans-
fer to a membrane, by immunoblotting as described below.
In the case of the large scale experiment (Fig. 2B), mitochon-
dria, prepared by differential centrifugation from 21 g of HeLa
S3 cells, were treated with 1% FA in buffer B (250 mM Sucrose,
10 mM KCl, 0.15 mMMgCl2, 20 mM HEPES, pH 7.2 (25 °C)) for
15 min. The FA was quenched by the addition of an equal vol-
ume of 250 mM glycine in buffer B. The mitochondrial pellet
was then lysed in 15 ml of buffer A, insoluble debris were
removed by centrifugation, and the resulting supernatant was
diluted 18-times with Tween-IP buffer. Protein complexes
were captured using purified anti-Mfn2 antibodies covalently
attached to Dynabeads-protein A (Dynal) with dimethyl pime-
limidate dihydrochloride, according to themanufacturer’s pro-
tocol, and were eluted with a buffer (500 mM NaCl, 100 mM
glycine, pH2.8 (25 °C)). The eluatewas neutralized and concen-
trated on an Amicon Ultra centrifugal device (Millipore). Pro-
teins were heat-treated, separated by SDS-PAGE, and detected
by silver staining, and selected protein bands were excised. The
further sample preparation and analysis was done by the Pro-
tein/PeptideMicroanalytical Laboratory at the California Insti-
tute of Technology. Briefly, gel slices were treated with
sequencing grade trypsin, and the resulting peptides were ana-
lyzed by liquid chromatography and tandem mass spectrome-
try (LC/MS/MS). The identified peptide sequences were
matched to theNational Center for Biotechnology Information
sequence data base using MASCOT software. The probabili-
ties-based Mowse scores and the coverage of the proteins with
the identified peptides were as follows (probability Mowse
score/sequence coverage in percent): Stoml2, 42A (430/26),
Stoml2, 42B (430/26), Mfn1 (500/28), Mfn2 (570/33).
For nondenaturing immunoprecipitation, 1  106 cells
were lysed in 0.8 ml of a co-IP buffer (0.5% digitonin, 120 mM
NaCl, Complete Mini protease inhibitor mixture, 50 mM
HEPES, pH 7.5 (25 °C)) for 15 min at 4 °C. The insoluble debris
were removed by centrifugation at 16,000 gav for 10min. The
resulting supernatants were incubated with the appropriate
antibodies and protein A-Sepharose as described above. The
immune complexes captured on Sepharose beads were centri-
fuged through a sucrose cushion (3.42 g of sucrose/10 ml of
co-IP buffer), washed three times with co-IP buffer and once
with co-IP buffer lacking digitonin, and further analyzed by
Western blotting.
Sample Preparation and Western Blot Analysis—To remove
contaminating rabbit IgGs present in the rabbit reticulocyte
lysate-based TNT T7-coupled transcription/translation sys-
tem, which could interfere, in the Western blot analysis, with
detection of in vitro synthesized Stoml2, samples of in vitro
synthesized Stoml2 were incubated with protein A-Sepharose
beads in an appropriate buffer (50 mM NaCl, 0.1 mM EDTA,
0.1% Tween 20, 25 mM Tris-HCl, pH 7.5 (25 °C)) for 1 h at 4 °C,
and the Sepharose beads were then removed by centrifugation.
The FA-cross-linked cells or FA-cross-linked purified mito-
chondria were incubated with buffer containing 2% SDS, 100
mM NaCl, and 10 mM Tris-HCl, pH 8.0 (25 °C) for 15 min and
then centrifuged to remove insoluble debris, and the resulting
extracts were used for Western blot analysis.
The total protein concentration in samples ofwhole cells, cell
extracts, or purifiedmitochondria was determined by the Brad-
fordmethod or by the bicinchoninic acidmethod (28, 29). Sam-
ples (whole cells, subcellular fractions, purified mitochondria,
protein A-Sepharose-treated in vitro synthesized proteins, or
immunoprecipitated proteins) were mixed with an equal vol-
ume of 2 Sample buffer and analyzed by SDS-PAGE. Rainbow
(Amersham Biosciences RPN756), Magic Mark XP (Invitro-
gen), or Kaleidoscope (Bio-Rad) size markers were analyzed
in parallel. Proteins were then electrophoretically trans-
ferred to a Hybond ECL nitrocellulose membrane (Amer-
sham Biosciences) in a previously described transfer buffer
(30)modified to contain 0.037% SDS. Blocking, first and second
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antibody incubations, and washes were carried out in PBSTw
(PBSplus 0.1%Tween 20) or PBSTwcontaining 5%nonfatmilk.
The specific protein complexes were identified by autoradiog-
raphy using the Super-Signal West Pico chemiluminescence
reagent (Pierce).
Fluorescence Microscopy and FACS Analysis—Cells were
grown in a chambered coverglass (Lab-Tek), and the medium
was replaced 12 h before an experiment. Cells were stained
with 25 nM tetramethylrhodamine ethyl ester perchlorate
(TMRE,Molecular Probes) or 50 nMMitotracker Red CMXRos
(Molecular Probes) in DMEM without serum for 30 min and
washed againwith culturemedium.Microscopywas performed
using an inverted Nikon Diaphot microscope equipped with a
Nikon G2A filter cube, a Zeiss Planapo 63/1.4 oil objective,
and a Nikon D50 digital camera. For FACS analysis, cells were
stained with 10 nM TMRE, trypsin-harvested, resuspended in
PBS containing 10 nM TMRE, and analyzed by a FACSCalibur
analyzer (Bio-Rad). Oxygen consumption measurements were
done as described previously (31).
Confocal Immunofluorescence Microscopy—Cells grown on
glass coverslips were sequentially incubated in 2% FA in PBS,
PBS, anhydrous methanol, PBS, and 2% goat serum in PBS
(GSPBS) containing 0.5% Triton X-100. The coverslips were
then incubated with anti-Stoml2 antibodies (C-186; diluted
1:50 in GSPBS) and anti-COXIV antibodies (diluted to 5g/ml
in GSPBS) for 3 h at 37 °C in a humidified chamber. As a nega-
tive control, nonimmune chicken IgY antibodies (Aves Labs)
were used instead of the anti-Stoml2 antibodies. After four
washes in GSPBS, the coverslips were incubated with 1:50-di-
luted fluorescein isothiocyanate-conjugated donkey anti-
chicken IgY and 1:50-diluted rhodamine Red-X-conjugated
goat anti-mouse IgG (both from Jackson ImmunoResearch
Laboratories) for 1 h at room temperature. After four washes in
PBS, the coverslips were mounted onto microscope slides in
FluoroGuard antifade reagent (Bio-Rad) and analyzed on a
Zeiss 410 laser-scanning microscope equipped with a 488-nm
argon and a 543-nm helium neon laser, a Zeiss 63/1.25 oil
objective, and Zeiss LSM software.
RESULTS
We used in vivo FA cross-linking of HeLa cells to preserve
Mfn2 protein complexes and to identify possible Mfn2-inter-
acting proteins. FA is a highly specific cross-linker that is reac-
tive with primary amines within 2 Å of one another, is easily
reversible, and is used to preserve protein-protein, protein-
DNA, or protein-RNA complexes (32). To detectMfn2, immu-
noblotting with antibodies generated against a large portion of
the Mfn2 protein was used. These antibodies detected a major
immunoreactive protein in the untreated cell lysates (Fig. 1A,
left panel, first lane), identified as Mfn2, as it was specifically
increased in amount when HeLa cells were transfected with an
Mfn2 expression vector (see Fig. 7B) and was specifically
reduced when HeLa cells were treated with siRNAMFN2 (see
Fig. 7C). The minor, slower migrating protein in the untreated
cell lysates (Fig. 1A, left panel, first lane) was identified asMfn1,
as it was specifically reduced in amount when HeLa cells were
treated with siRNAMFN1 (see Fig. 7C). When HeLa cells were
treatedwith 1%FA for 15min, highmolecularweight FA-cross-
linked products were detected by immunoblotting with anti-
Mfn2 antibodies (Fig. 1A, left panel). Longer FA treatments led
to a loss of the distinct high molecular weight bands immuno-
reactive with anti-Mfn2 antibodies (Fig. 1A, left panel). Because
anti-Mfn2 antibodies weakly cross-react withMfn1, it was pos-
sible that at least some of the anti-Mfn2 immunoreactive cross-
linked products were due to the presence of Mfn1. Further-
more, Mfn2 has been shown to interact with Mfn1 (5, 9).
However, almost no high molecular weight cross-linked prod-
ucts were detected on immunoblots treated with anti-Mfn1
antibodies (Fig. 1A, right panel). This indicates that the ladder-
like bands consist specifically of Mfn2 homo- or hetero-oli-
gomers and that most of the cross-linked Mfn1 products were
not soluble or were not electrotransferred. In addition, a single,
faster migrating, cross-linked product was detected with anti-
Mfn2 or anti-Mfn1 antibodies, suggesting the presence of
FIGURE 1. Formaldehyde cross-linking reveals Mfn2 oligomerization.
A, HeLa CCL2 cells were treated for 0, 15, or 60 min with FA, and SDS cell
lysates were analyzed by Western blotting with anti-Mfn2 or anti-Mfn1 anti-
bodies. Some samples of SDS lysateswere heated to reverse the cross-linking
(revers.) as indicated. B, HeLa CCL2 cells or purified mitochondria obtained
from HeLa S3 cells were treated for 0, 1, 5, or 15 min with FA, and their SDS
lysates were analyzed by Western blotting with anti-Mfn2 antibodies. High
exposures are shown for the purpose of visualization of the high molecular
weight cross-linked bands. Under these conditions the intensities of the
monomeric bands are underrepresented.
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intramolecularly cross-linkedMfn2 andMfn1 products (Fig. 1).
Fiveminutes of FA cross-linking ofwhole cells led to an optimal
resolution of the ladder-like pattern detected with anti-Mfn2
antibodies while minimizing products barely entering the gel
(Fig. 1B). For a number of reasons, including the unequal effi-
ciencies of transfer of small versus large proteins, the signals on
a Western blot do not give an accurate representation of the
amount of target protein. Nevertheless, to obtain an approxi-
mation of the levels of Mfn2 in the various bands on the blots,
we quantified the chemiluminescent signals of the blots on film
exposures lower than those shown in Fig. 1B. Thus, after 5 min
of FA treatment, and relative to the amount of Mfn2 present in
the untreated sample,12% of the total Mfn2 was estimated to
be present as the uncross-linked Mfn2 monomer,16% as the
internally cross-linked Mfn2, and 8% as the discrete high
molecularweight cross-linked products. Someof the remaining
unaccounted for (64%) Mfn2 protein was present in high
molecular weight heterogeneousmaterial. The rest was not sol-
uble or was not electrotransferred. Short times of cross-linking
(1–15 min of FA treatment) resulted in a relatively constant
amount of Mfn2 (6–9%) present in discrete high molecular
weight cross-linked products. Importantly, a reversion of the
cross-linking resulted in conversion of most of the soluble
cross-linked species back to Mfn2 and Mfn1 monomers (Fig.
1A). Most of the high molecular weight Mfn2-immunoreactive
products were detected not only by FA cross-linking of whole
cells but also by FA cross-linking in organello, that is by cross-
linking of highly purified mitochondria, indicating that the
putative Mfn2 complexes are preserved in isolated mitochon-
dria (Fig. 1B).
Identification of Stomatin-like Protein 2 (Stoml2)—To ana-
lyze the composition of the formaldehyde-cross-linked oli-
gomers, SDS lysates of [35S]Met-labeled and FA-cross-linked
HeLa cells were immunoprecipitated with anti-Mfn2 antibod-
ies, and the cross-linking was reversed by heating the immuno-
precipitates to 95 °C to release individual proteins (Fig. 2A).
Several proteins appeared to be specifically precipitated with
anti-Mfn2 antibodies only when cells had been treatedwith FA.
Among them, a 42-kDa protein was detected (Fig. 2A). The
42-kDa protein was not detected in FA-cross-linked cells
immunoprecipitated with preimmune serum or anti-Mfn1
antibodies (data not shown). Previous experiments indicated
that a similar pattern of the Mfn2-immunoreactive complexes
is observed if purifiedmitochondria are used for the cross-link-
ing (Fig. 1B). Indeed, the 42-kDa protein was also detected
by FA cross-linking in organello and immunoprecipitation
with anti-Mfn2 antibodies (data not shown). Large scale
preparation of the Mfn2 immunoprecipitate of FA-cross-
linked mitochondrial fraction yielded two dominant protein
bands, 42A and 42B, as well as 74- and 70-kDa proteins,
detected by silver staining (Fig. 2B). LC/MS/MS analysis of
trypsin digests identified both the 42A and 42B bands as
Stoml2. Most likely, the 42B form of Stoml2 was generated by a
nonspecific proteolysis during the large scale purification,
because only a singleton bandwas detected by immunoblotting
with anti-Stoml2 antibodies of whole cell lysates (see Fig. 5A).
The LC/MS/MS analysis also confirmed that the 74-kDa pro-
tein isMfn1 and the 70-kDa protein isMfn2. The relatively high
amount of Mfn1 in the immunoprecipitate, when compared
with Mfn2, is likely because of contributions of the immuno-
precipitated Mfn1-Mfn2 cross-linked products as well as the
cross-reactivity of the anti-Mfn2 antibodies withMfn1. Impor-
tantly, anti-Stoml2 antibodies detected Stoml2 in the anti-
Mfn2 immunoprecipitate prepared from FA-cross-linked cells
but failed to detect the Stoml2 in the anti-Mfn2 immunoprecipi-
tate prepared from cells without cross-linking (Fig. 2C). About
10% of total cellular Stoml2 was precipitated with anti-Mfn2 anti-
bodies in this experiment. Thus, we confirmed the presence of
Stoml2 inMfn2-containing FA-cross-linked products, suggesting
the presence ofMfn2-Stoml2 hetero-oligomers.
FIGURE 2. Stoml2 is specifically immunoprecipitated with Mfn2 anti-
bodies fromFA-cross-linked cells.A, [35S]Met-labeledHeLa CCL2 cells were
treated with FA, lysed, immunoprecipitated with either preimmune serum
(pre-i) or anti-Mfn2 antibodies, heat-treated to 95 °C to reverse cross-linked
products (indicated as revers.), and analyzed by SDS-PAGE and autoradiogra-
phy. Time (inminutes) of FA treatment is indicated. The nonspecific47- and
52-kDabandswere absent in theHeLa S3 immunoprecipitates (not shown).
B, the mitochondrial fraction, prepared by differential centrifugation from
HeLa S3 cells, was treated with FA for 15 min, lysed with SDS, and immuno-
precipitated with anti-Mfn2 antibodies attached to magnetic beads. The
resulting immunoprecipitate was heat-treated and analyzed by SDS-PAGE
and silver staining. C, HeLa CCL2 cells were treated as indicatedwith FA for 15
min, lysed with SDS, immunoprecipitated with either preimmune serum or
anti-Mfn2 antibodies, heat-treated, and analyzed by Western blotting with
Stoml2 antibodies. In parallel, 1% of total cell lysate used for immunoprecipi-
tation (1% of input) was analyzed.
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Mitochondrial Localization of Stoml2—Stoml2 had previ-
ously been reported to be a plasma membrane-associated pro-
tein of unknown function (33). However, several proteomics
studies have detected Stoml2 in purified mitochondria, and,
importantly, in one study, hemagglutinin-tagged Stoml2 was
found to co-localize with a mitochondrial marker (34–37). To
confirm the mitochondrial localization, we carried out an indi-
rect immunocytochemistry experiment using anti-Stoml2 anti-
bodies. Images obtained by confocal fluorescence microscopy
revealed that the endogenous Stoml2 co-localizes with a mito-
chondrial marker, COXIV, in HeLa cells (Fig. 3A). In addition,
cell fractionation followed by immunoblotting revealed that
Stoml2 co-fractionates with the mitochondrial markers porin
and COXIV. Furthermore, it was highly enriched in purified
mitochondria, which appeared to be free of a cytosolic marker,
enolase (Fig. 3B).
Submitochondrial Localization of Stoml2—To determine
whether Stoml2 is a membrane-bound or soluble mitochon-
drial protein, purified mitochondria were treated with sodium
chloride, sodium carbonate, or Triton X-100, and the resulting
washes and mitochondrial membrane-containing pellets were
analyzed by immunoblotting (Fig. 4A). Stoml2 remained asso-
ciated with the membrane fraction after sodium chloride treat-
ment, which removes soluble mitochondrial proteins, and even
after the sodium carbonate treatment, which stripped off the
F1-ATPase -subunit, a peripheral membrane protein (38).
Stoml2 was nearly completely solubilized from the mitochon-
drial membranes by 1% Triton X-100 treatment, which only
partially solubilized the F1-ATPase -subunit and the integral
membrane protein COXII, while failing to solubilize another
integral membrane protein, prohibitin. Because Stoml2 has no
predicted transmembrane domain, its integral membrane pro-
tein-like behavior may be due to a post-translational modifica-
tion, such as a fatty acylation or glycosylphosphatidylinositol
modification, which mediates the membrane anchoring.
To dissect the Stoml2 submitochondrial localization further,
purified mitochondria were treated with increasing concentra-
tions of digitonin in the presence of proteinase K, and the
resulting fractions were analyzed by immunoblotting (Fig. 4B).
Bcl2, an outer mitochondrial membrane protein that faces the
cytosol, was sensitive to proteinase K even in the absence of
digitonin. Full-length Stoml2, detected with antibodies against
the C-terminal half of the protein (Stoml2-C) or with antibod-
ies against the N-terminal half of the protein (Stoml2-N), was
sensitive to proteinase K digestion at about the same digitonin
concentrations needed to digest the intermembrane space pro-
tein Opa1. Under these conditions, the mitochondrial matrix
marker F1-ATPase-subunitwas largely resistant to proteinase
K digestion. Proteinase K treatment under higher digitonin
concentrations led to the generation of a proteolytic fragment
of Stoml2 that could be detected by either anti-Stoml2-C or
anti-Stoml2-N antibodies. The detection of this fragment sug-
gests that a part of Stoml2 is inaccessible to the protease, per-
haps because of a tight membrane association. Overall, these
experiments indicated that Stoml2 is at least partially exposed
to the mitochondrial intermembrane space compartment. The
partial sensitivity of Opa1 and Stoml2 to proteinase K in the
absence of digitonin is likely due to the presence in the mito-
chondrial preparation of somemitochondria with broken outer
membranes, and therefore this result did not affect the inter-
pretation of the experiments.
In the course of analysis of Stoml2, we noticed that Stoml2
synthesized in vitro from human cDNA migrates more slowly
than the endogenous Stoml2 of HeLa cells (Fig. 5A). This phe-
FIGURE 3. Stoml2 is amitochondrial protein. A, HeLa CCL2 cells were fixed, processed for indirect immunocytochemistry, and analyzed by confocal fluores-
cence microscopy. Representative images of cells stained with anti-Stoml2 antibodies (or nonimmune Ig, in green) or anti-COXIV antibodies (in red) and
merged images are shown. B, HeLa CCL2 cells were fractionated, and the resulting mitochondrial fraction was further purified on a Percoll/metrizamide
gradient. Selected fractions (10g of protein) were analyzed byWestern blotting with anti-Stoml2, anti-enolase, anti-porin, or anti-COXIV antibodies. Lane 1,
whole cell homogenate; lane 2, 1300 g supernatant; lane 3, 6700 g supernatant; lane 4, 6700 gpellet; lane 5, Percoll/metrizamide-purifiedmitochondria.
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nomenon is often an indication of a proteolytic processing that
accompanies the import of some proteins into the mitochon-
drial matrix or the inner membrane or the intermembrane
space. Therefore, we carried out an import experiment using
Stoml2 synthesized in vitro and import-competent mitochon-
dria prepared from HeLa cells (Fig. 5B). Compared with the in
vitro synthesized (precursor) form of Stoml2, a faster migrating
(mature) form of Stoml2 was detected upon incubation of the
precursor with mitochondria. This mature form of Stoml2 was
resistant to subsequent proteinase K treatment of intact mito-
chondria but was sensitive to proteinase K treatment of Triton
X-100-solubilized mitochondria. In addition, the mature form
of Stoml2 was not detected if the import reaction was carried
out in the presence of the ionophore carbonyl cyanide p-(tri-
fluoromethoxy)phenylhydrazone, which dissipates the mito-
chondrial membrane potential across the inner mitochondrial
FIGURE 4.Mitochondrial sublocalization of Stoml2. A, membrane associa-
tion of Stoml2. Purified mitochondria prepared from HeLa S3 cells were dis-
ruptedbyhypotonic shock (control) and treatedwith 1.5 MNaCl, 0.1 MNa2CO3
(pH 11.5), or 1% Triton X-100. After the treatment, mitochondrial membranes
(m) were separated from solublematerial (s), as detailed under “Experimental
Procedures,” and both fractionswere analyzed byWestern blottingwith anti-
Stoml2, anti-F1-ATPase -subunit, anti-prohibitin, or anti-COXII antibodies.
B, proteinase K sensitivity of Stoml2. Purified mitochondria were left untreated,
treated with proteinase K, or treated with proteinase K in the presence of
increasing concentrationsof digitonin andanalyzedbyWesternblottingwith
anti-Stoml2-C, anti-Stoml2-N, anti-Bcl-2, anti-Opa1, or anti-F1-ATPase -sub-
unit antibodies.
FIGURE 5. Stoml2 import into isolated mitochondria is dependent on
mitochondrial membrane potential and is accompanied by proteolytic
processing. A, electrophoretic mobility of Stoml2. In vitro synthesized
[35S]Met-labeled Stoml2 (2 or 4l) from a vector carrying STOML2 cDNA, the
products of a control reaction carried out in the presence of an empty vector,
as well as 10 g of HeLa CCL2 cell lysate were analyzed by Western blotting
with anti-Stoml2 antibodies. B, Stoml2 import. In vitro synthesized [35S]Met-
labeled Stoml2 was incubated with isolated mitochondria and in some sam-
ples, as indicated, in the presence also of carbonyl cyanide p-(trifluorome-
thoxy)phenylhydrazone (FCCP) as detailed under “Experimental Procedures.”
Following import, samples were left untreated, treated with proteinase K, or
treated with proteinase K and 1% Triton X-100. After centrifugation, the
resulting pellet (p) and supernatant (s) fractions were analyzed by SDS-PAGE
and autoradiography. In parallel, 5% of the in vitro synthesized Stoml2, used
for the import reaction, was analyzed (5% of input). The in vitro synthesized
Stoml2 (precursor) and the imported and processed form of Stoml2 (mature)
are each indicated by an arrowhead.
FIGURE 6. Mfn2 and Stoml2 form a complex. HeLa CCL2 cells were lysed
with digitonin and immunoprecipitated with preimmune serum (pre-i) or
anti-Mfn2 or anti-Mfn1 antibodies. The resulting immunoprecipitates and 1%
of total cell lysate used for immunoprecipitation (1% of input) were analyzed
by Western blotting with anti-Stoml2 antibodies.
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membrane. We concluded that Stoml2 is imported into mito-
chondria in amembrane potential-dependent manner and that
the import is accompanied by proteolytic processing. The sub-
localization and import experiments together suggest that
Stoml2 is an intermembrane space protein.
Stoml2 Forms aHighMolecularWeight ComplexwithMfn2—
To control for potential artifacts of FA cross-linking, co-im-
munoprecipitation of digitonin cell lysates with anti-Mfn2
antibodies followed by immunoblotting with anti-Stoml2
antibodies was performed (Fig. 6). Anti-Mfn2 antibodies, but not
preimmune serum or anti-Mfn1 antibodies, co-precipitated
Stoml2 protein, thus confirming the occurrence of a specific
Mfn2-Stoml2 complex.
To address the question of whether Stoml2 is present in high
molecular weight Mfn2-containing oligomers detected by FA
cross-linking, experiments similar
to those described in Fig. 1were car-
ried out (Fig. 7). It should be noted
first that anti-Stoml2 antibodies did
not cross-react with Mfn2 and that
anti-Mfn2 antibodies did not cross-
react with Stoml2 (Fig. 7 and data
not shown). In control cells (mock),
immunoblotting with anti-Mfn2
antibodies or with anti-Stoml2 anti-
bodies detected identical ladders of
FA-cross-linked high molecular
weight oligomers (Fig. 7A, red
arrows). These immunoreactive
ladders were not observed in the
absence of the cross-linker. The
anti-Mfn2 antibodies weakly cross-
reacted with unidentified 52- and
47-kDa proteins (Western blot data
not shown), migrating as a single
band in Fig. 7 (marked by an aster-
isk). These proteins, however, could
not contribute to the high molecu-
lar weight cross-linked oligomers,
because they were absent in mito-
chondrial fractions, which, upon FA
treatment, gave a similar pattern of
the high molecular weight oli-
gomers (data not shown). Impor-
tantly, the pattern of highmolecular
weight cross-linked products was
specifically detectedwith anti-Mfn2
or anti-Stoml2 antibodies but not
with anti-actin, anti--tubulin,
anti-Opa1, or anti-prohibitin anti-
bodies (data not shown).
When cells were treated for 4
days with siRNA directed against
STOML2 mRNA, which reduced
the Stoml2 protein levels to 20%
compared with the mock-treated
controls, the FA-cross-linked prod-
ucts detected with both anti-Mfn2
and anti-Stoml2 antibodies were dramatically decreased (Fig. 7A,
red arrows). When HeLa cells were transfected with a Stoml2
expression plasmid, which led to an estimated 4–5-fold
increase in Stoml2 protein levels, the FA-cross-linked products
detected with both anti-Mfn2 and anti-Stoml2 antibodies were
dramatically increased (Fig. 7B, red arrows). Under the condi-
tions of Stoml2 down-regulation and also Stoml2 up-regula-
tion, the endogenous levels of Mfn2 did not change (Fig. 7, A
and B, and results not shown).
When cells were transfected with Mfn2 expression plasmid,
which led to an estimated 3–4-fold increase in the Mfn2 pro-
tein, the FA-cross-linked products detected with both anti-
Mfn2 and anti-Stoml2 antibodies were not significantly
increased. Instead, a smeary Mfn2-immunoreactive pattern
was observed under these conditions, an indication of nonspe-
FIGURE 7. Stoml2 andMfn2 form large complexes capturedby FA cross-linking.A, mock-transfectedHeLa
CCL2 cells (i.e. cells transfectedwith the lipid carrier) or cells transfectedwith siRNASTOML2were treatedwith FA
for the indicated periods of time (inminutes), lysedwith SDS, and analyzedbyWestern blottingwith anti-Mfn2
antibodies followed by reblotting with anti-Stoml2 antibodies. B, cells transfected with an empty vector, a
vector carrying STOML2 cDNA, or a vector carrying MFN2 cDNA were treated and analyzed as described in A.
C, mock-transfected HeLa CCL2 cells or cells transfected with siRNAMFN1, siRNAMFN2, or siRNAMFN1/siRNAMFN2
were treated and analyzed as described in A. High exposures are shown for the purpose of visualization of the
highmolecular weight cross-linked bands; under these conditions the intensities of themonomeric bands are
underrepresented. Cross-linked products containing Mfn2 and Stoml2 are indicated with red arrows, Mfn1
monomers with a black arrow, Mfn2 monomers with a green arrow, intramolecularly cross-linked Mfn2 with a
purple arrow, cross-linked product containing Stoml2, but not Mfn2, with an orange arrow, Stoml2 monomers
with a blue arrow, and an unidentified band cross-reacting with anti-Mfn2 antibodies with an asterisk.
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cific cross-linked products probably resulting fromMfn2 over-
expression (Fig. 7B). When HeLa cells were treated for 4 days
with siRNA directed against MFN2 mRNA, which reduced the
Mfn2 protein levels to5%when comparedwithmock-treated
controls, the FA-cross-linked products generated by a 1- or
5-min FA treatment and detected with both anti-Mfn2 and
anti-Stoml2 antibodies were not significantly decreased (Fig.
7C, red arrows). Under these conditions of Mfn2 down-regula-
tion, we observed a strong up-regulation of Mfn1 (2.8-fold).
To address the question of whether Mfn1 can substitute for
Mfn2 in the complexes with Stoml2, the cells were treated with
siRNAMFN1, alone or in combination with siRNAMFN2, and
then were analyzed as described above. However, neither
down-regulation of Mfn1 alone or in combination with down-
regulation ofMfn2 led to a significant decrease in the FA-cross-
linked products detected with both anti-Mfn2 and anti-Stoml2
antibodies (Fig. 7C, red arrows). Thus, the residual Mfn2 after
siRNAMFN2 treatment appears to be in amounts sufficient for
the formation of the Mfn2-Stoml2 complex. Possibly Mfn2 is
stabilized by its association with Stoml2 and therefore persists
even after siRNAMFN2 treatment. Interestingly, under the con-
ditions ofMfn1 down-regulation, we observed a significant up-
regulation of Mfn2. Under the conditions of down-regulation
of both Mfn1 and Mfn2, there was still about 10% residual
Mfn2 protein when compared with themock-treated cells. The
down-regulation and up-regulation experiments described
above clearly demonstrate that Stoml2 is a limiting component
of the Stoml2-Mfn2 complex. The Mfn2 down-regulation and
up-regulation experiments suggest that only a small portion of
the cellular Mfn2 is involved in forming the Mfn2-Stoml2 het-
ero-oligomers. The quantification of the discrete high molecu-
lar weight cross-linked species (8% in the four major discrete
species) in Fig. 1B supports this idea.
Among the cross-linked products detected by Stoml2 anti-
bodies, but not byMfn2 antibodies, one had an apparentmolec-
ular mass of75 kDa and could represent a Stoml2 dimer (Fig.
7, orange arrows). A larger cross-linked product, with a molec-
ular mass of 139 kDa, was immunoreactive with both Mfn2
and Stoml2 antibodies and therefore could represent a hetero-
trimer composed of one molecule of Mfn2 and two molecules
of Stoml2. The higher molecular weight hetero-oligomers are
regularly spaced from each other at50–70 kDa intervals.
What Is the Function of Stoml2?—Mitochondrial morphol-
ogy is determined by a dynamic equilibrium of two opposing
processes, mitochondrial fusion and mitochondrial fission.
Depletion ofMfn2 leads to the disruption of the fusion process,
and the consequent prevailing mitochondrial fission leads to a
fragmented type ofmitochondrialmorphology (39). To address
the function of Stoml2 inmitochondrial fusion, HeLa cells were
treated with siRNASTOML2, and the effect on mitochondria,
stained with the mitochondria-specific dye MitoTracker Red,
was determined. An improved protocol of siRNASTOML2 treat-
ment led to a dramatic decrease in Stoml2 protein levels (Fig.
8A).When these were normalized to the levels of-tubulin, the
20 or 100 nM siRNASTOML2-treated cells had only 2–5% resid-
ual levels of Stoml2 as comparedwithmock-treated cells. How-
ever, under these conditions, no dramatic change of mitochon-
drial morphology in cells treated with siRNASTOML2 and
stained with 50 nM MitoTracker Red was observed when com-
pared with mock-treated cells (data not shown).
Although a reduction of Stoml2 protein levels does not
appear to change mitochondrial morphology, we observed a
clear decrease of MitoTracker Red fluorescence under these
conditions of siRNASTOML2 treatment (data not shown). To
address the question of whether the mitochondrial membrane
potential is compromised if Stoml2 is down-regulated, HeLa
cells were treated with siRNASTOML2 as described above and
stained with the potentiometric dye TMRE (Fig. 8B). When
compared with mock-treated HeLa cells, the cells treated with
siRNASTOML2 exhibited a clear reduction of the mitochondria-
associated TMRE fluorescence intensity, an indication of
decreased mitochondrial membrane potential. In contrast,
treatment of HeLa cells with siRNAMFN2, that led to a decrease
of the Mfn2 levels to5%, did not noticeably affect the TMRE
fluorescence intensity (data not shown). To confirm the spe-
cific effect of Stoml2 reduction on the mitochondrial mem-
brane potential, mock-treated cells and cells treated with 20 or
100 nM siRNASTOML2were stainedwithTMRE and analyzed by
FIGURE 8. Stoml2 knockdown experiments reveal reduced mitochondrial
membranepotential inHeLaCCL2cells.A, indicatedamountsofmock-treated
cellsorcells treatedwith20nMsiRNASTOML2orwith100nMsiRNASTOML2 for6days
wereanalyzedbyWesternblottingwithanti-Stoml2oranti--tubulinantibodies.
B, sets of three representative images of cells treated as described in A and
stainedwith 25 nM TMRE.
TABLE 1
FACS analysis of HeLa cells
Mock-treated HeLa cells or cells treated with siRNASTOML2, as described under
“Experimental Procedures,” were stained with 10 nM TMRE to equilibrium and
analyzed by FACS.
siRNASTOML2 Fluorescence
geometric mean
Mock 540.7
20 nM 453.1
100 nM 438.4
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FACS. Consistent with the previous observations, cells treated
with 20 and 100 nM siRNASTOML2 exhibited, respectively, an
16% and an19% decrease in the geometric mean of TMRE
fluorescencewhen comparedwithmock-treated cells (Table 1).
Importantly, the treatment of HeLa cells with 20 or 100 nM
siRNASTOML2 did not affect the rate of oxygen consumption in
intact cells driven by the endogenous substrates, the maximal
rate of oxygen consumption in dinitrophenol-uncoupled
mitochondria, or the rate of oxygen consumption driven by
ascorbate/N,N,N,N-tetramethyl-1,4-phenylenediamine in
the presence of antimycin A (data not shown).
DISCUSSION
In the present work, we have identified a complex between
the mitochondrial fusion mediator Mfn2 and Stoml2. The ini-
tial evidence for the occurrence of this complexwas obtained by
the use of in vivo cross-linking of HeLa cells with formaldehyde
and immunoprecipitation with anti-Mfn2 antibodies. An42-
kDa protein, which was specifically immunoprecipitated with
Mfn2 antibodies, was then identified as Stoml2. The presence
of an endogenous Mfn2-Stoml2 complex was subsequently
confirmed by a co-immunoprecipitation experiment using cells
lysed with digitonin. In this experiment, Stoml2 was detected
by immunoblotting in the immunoprecipitate obtained with
anti-Mfn2 antibodies. This interaction with Stoml2 appeared
to be specific for Mfn2, because an immunoprecipitation with
Mfn1 antibodies did not yield Stoml2.
The human Stoml2 gene had been cloned and characterized
previously (33, 40). Stoml2 is a member of the stomatin super-
family because of its stomatin consensus signature sequence
(33). Human Stoml2 and stomatin have, however, very low
overall homology (20% similarity at the amino acid level), and
Stoml2 lacks the typical N-terminal transmembrane domain
present in other stomatins. Previous studies have suggested
that Stoml2 is associated with the plasmamembrane and other
cellular membranes, on the basis of immunocytochemistry of
human erythrocytes (33). In our work, however, Stoml2 was
found to co-localize with mitochondrial markers both in
immunocytochemical and cell fractionation experiments, and
we did not detect any plasmamembrane staining in our immu-
nocytochemical experiments. A sequence analysis of the
Stoml2 N terminus using theMitoProt II program revealed the
high probability (98%) of its carrying a mitochondrial targeting
sequence. Indeed, we found that Stoml2 is efficiently imported
into isolatedmitochondria. The import is accompanied by pro-
teolytic processing and is dependent on an intactmitochondrial
membrane potential. Our results are supported by several pro-
teomic studies reporting the presence of Stoml2 in mitochon-
dria (35–37). In addition, hemagglutinin-tagged Stoml2 was
found to be localized in mitochondria in one of these studies
(35). Thus, our work has confirmed that Stoml2 is indeed a
mitochondrial protein. The above discussed findings suggest-
ing that Stoml2 is associated with the plasma membrane may
reflect situations in specialized cells, such as erythrocyte ghosts,
which lack mitochondria or need to be revisited.
Subsequently, we found that Stoml2 is associated with mito-
chondrial membranes and exhibits an integral membrane pro-
tein-like behavior. As mentioned above, sequence analysis of
Stoml2 did not predict the presence of a transmembrane
domain, and thus the nature of the Stoml2 attachment to the
mitochondrial membranes is presently unclear. In this regard,
it was suggested that membrane attachment of stomatin is
mediated not only by its transmembrane domain but also by the
recently discovered palmitoylation of stomatin (41). A similar
post-translational modification of Stoml2 could also mediate
its membrane association. In the present work, further sublo-
calization studies showed that Stoml2 was not sensitive to
externally added protease in intact mitochondria, but it was
sensitive in mitochondria treated with a low concentration of
digitonin. This treatment produced the protease sensitivity of
an intermembrane space marker but not of a mitochondrial
matrix marker. Thus, our experiments have indicated that
Stoml2 is localized in the mitochondrial intermembrane space.
The characteristics of the import of Stoml2 into the mitochon-
dria, discussed above, are typical of mitochondrial proteins
localized in the matrix or the inner membrane or intermem-
brane space but not for proteins of the outer mitochondrial
membrane. These characteristics and our data on the submito-
chondrial localization of Stoml2 suggest that Stoml2 is associ-
ated with the inner mitochondrial membrane and projects
toward the intermembrane space. However, we cannot for-
mally exclude the possibility that Stoml2 is associated with the
outer mitochondrial membrane.
As far as the Mfn2-Stoml2 complex is concerned, immuno-
blotting of cell lysates prepared from FA-cross-linked cells
detected a ladder-like pattern of products containing both
Mfn2 and Stoml2. These FA-cross-linkedproductswere strongly
decreased in amountwhen the cellular Stoml2was reduced by the
use of siRNA treatment, whereas they were increased when cellu-
lar Stoml2 was overexpressed. However, the FA-cross-linked
productswerenot significantlychanged inamountwhentheMfn2
protein levels were manipulated. These results suggest that
Stoml2 is a limiting component of the Mfn2-Stoml2 complex
and that only a small fraction of the cellular Mfn2 is present in
the complex. Using formaldehyde cross-linking, we were not
able to detect cross-linked products containing both Mfn1 and
Mfn2 by Western blotting. This could be because of an insolu-
bility of cross-linked Mfn1-Mfn2 complex or because of low
endogenous levels of the Mfn1-Mfn2 complex. Indeed, this
complex was detected only in overexpression systems (5, 9).
However, a large scale preparation of proteins cross-linked
to Mfn2 revealed, after reversal of the cross-linking, that
about equal amounts of Mfn1 and Mfn2 were co-purified
(Fig. 2B), strongly suggesting the existence of Mfn1-Mfn2
hetero-oligomers.
The immunoblotting of formaldehyde cross-linked cells with
anti-Stoml2 antibodies (but not with anti-Mfn2 antibodies)
detected an75-kDa product, which could represent a Stoml2
dimer. Higher molecular weight species of140 kDa, reactive
with both antibodies, might represent a trimer consisting of
two molecules of Stoml2 and one molecule of Mfn2. Interest-
ingly, at least seven additional bands with regular spacing of
50–70 kDa were detected with both antibodies. However, we
predict that not all of the detected cross-linked species are pres-
ent in vivo but rather that they were the result of incomplete
cross-linking of the complex.Our observation that longer times
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of the cross-linking reaction lead to a shift of the cross-linked
products toward higher molecular weight species is consistent
with this prediction. It is also possible that other proteins were
present in the detected Stoml2-Mfn2 complex. Following this
model, Stoml2 might form an important scaffold in the mito-
chondrial inner membrane with which the outer membrane
fusion machinery interacts. Interestingly, in this regard, we
observed a small but reproducible reduction of mitochondrial
membrane potential in cells treated with siRNASTOML2. It is
thus possible that a disturbed organization of the Stoml2 scaf-
fold leads to a decrease in mitochondrial membrane potential.
With regard to the Stoml2 function in mitochondrial fusion,
no obvious changes in mitochondrial morphology were
detected when HeLa cells were treated with siRNASTOML2,
although these conditions reduced the Stoml2 protein levels to
5% as compared with mock-treated cells. In a similar experi-
ment, siRNA reduction of Mfn2 to 5% also had no dramatic
effect on mitochondrial morphology (data not shown). Thus,
the negative results obtained with siRNASTOML2 could result
from a limitation of the siRNA technology, which does not
always produce a complete depletion of the desired protein in
the cell. Treatment of cells with siRNAs directed against both
Mfn1 and Mfn2, however, caused a change in mitochondrial
morphology characterized by punctate mitochondria (data not
shown). In this light, the results of the siRNAMFN2 experiment
could be explained by overlapping functions ofMfn2 andMfn1
in fusion as reported previously (5). Furthermore, it is also pos-
sible that a protein homologous to Stoml2 exists and substitutes
for a possible Stoml2 function in mitochondrial fusion. Inter-
estingly, a prohibitin homology domain can be detected within
the Stoml2 amino acid sequence. Thus, perhaps, a prohibitin
can substitute for Stoml2. Yeast prohibitins are mitochondrial
proteins anchored in the inner mitochondrial membrane and
projecting into the intermembrane space (42). They form large
oligomeric complexes, which have been suggested to function
as regulators of protein degradation by m-AAA protease or as
molecular chaperones for mtDNA-encoded proteins (43–45).
In addition, the formation of prohibitin ring structures with
outer dimension of270 200 Å has recently been reported,
and their scaffolding function in themitochondrial innermem-
brane has been suggested (42). The ring structures of prohib-
itins may also be important for the maintenance of mitochon-
drial morphology. Previous reports demonstrated that, in the
absence of prohibitins, fragmentedmitochondria occur in yeast
cells lackingmtDNAor in theCaenorhabditis elegans bodywall
muscle cells (46–48). Further work is needed to clarify the
functional relevance, if any, of Stoml2 in the formation of an
inner membrane scaffold and in themaintenance of mitochon-
drial morphology.
The coordination of the outer membrane and the inner
membrane fusion events is not understood at present. The
importance of the intermembrane space loop of the yeast mito-
fusin homolog Fzo1 for its interaction with the mitochondrial
inner membrane and for normal mitochondrial morphology
has been demonstrated previously (49). It was also suggested
that this interaction is mediated via an unknown protein of the
inner mitochondrial membrane. On the basis of the intermem-
brane space/inner membrane localization of Stoml2, we spec-
ulate that Stoml2 may interact with the intermembrane space
loop ofMfn2. This loop contains a tryptophan residue (Trp-631
of Mfn2), highly conserved among mitofusin/Fzo proteins.
Interestingly, it has been reported that COS7 cells expressing
the Mfn2W631P mutant protein exhibit fragmented mitochon-
dria, even though the localization of the mutant Mfn2 is unaf-
fected (50).
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Note Added in Proof—A new protein involved in mitochondrial
fusion in mammalian cells has recently been identified (Choi, S. Y.,
Huang, P., Jenkins, G.M., Chn, D. C., Schiller, J., and Frohman,M. A.
(2006) Nat. Cell Biol. 8, 1255–1262).
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